1AD — Adalta Share Price
Last Trade - 00:00- AU$22.80m
- AU$14.74m
- AU$4.25m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 30th Jun | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.75 | 1.97 | 2.08 | 3.59 | 3.85 | 3.24 | 3.28 | 34.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.
Directors
- Paul MacLeman CHM
- Timothy Oldham
- Dallas Hartman
- Michael Foley
- Kate Griffiths
- Cameron Jones
- Elizabeth McCall
- James Williams
- David Fuller
- Robert Peach (62)
- Rosalind Wilson
- Last Annual
- June 30th, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- June 22nd, 2006
- Public Since
- August 22nd, 2016
- No. of Shareholders
- 1,100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 245,175,853
- Address
- Shop 14 330 Collins St, MELBOURNE, 3000
- Web
- http://www.adalta.com.au/
- Phone
- +61 394795159
- Auditors
- Butler Settineri (Audit) Pty Ltd
Latest News for 1AD
Upcoming events for 1AD
Adalta Ltd Annual Shareholders Meeting
Similar to 1AD
ACTINOGEN MEDICAL ORD
Australian Stock Exchange - SEATS
ALTERITY THERAPEUTICS ORD
Australian Stock Exchange - SEATS
ANATARA LIFESCIENCES ORD
Australian Stock Exchange - SEATS
ANTEOTECH ORD
Australian Stock Exchange - SEATS
ARGENICA THERAPEUTICS ORD
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:56 UTC, shares in Adalta are trading at AU$0.09. This share price information is delayed by 15 minutes.
Shares in Adalta last closed at AU$0.09 and the price had moved by -15.45% over the past 365 days. In terms of relative price strength the Adalta share price has underperformed the ASX All Ordinaries Index by -33.02% over the past year.
The overall consensus recommendation for Adalta is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Adalta does not currently pay a dividend.
Adalta does not currently pay a dividend.
Adalta does not currently pay a dividend.
To buy shares in Adalta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.09, shares in Adalta had a market capitalisation of AU$22.80m.
Here are the trading details for Adalta:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: 1AD
Based on an overall assessment of its quality, value and momentum Adalta is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adalta is AU$0.18. That is 93.55% above the last closing price of AU$0.09.
Analysts covering Adalta currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adalta. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -54.17%.
As of the last closing price of AU$0.09, shares in Adalta were trading -32.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adalta.
Adalta's management team is headed by:
- Paul MacLeman - CHM
- Timothy Oldham -
- Dallas Hartman -
- Michael Foley -
- Kate Griffiths -
- Cameron Jones -
- Elizabeth McCall -
- James Williams -
- David Fuller -
- Robert Peach -
- Rosalind Wilson -
We do not have data on Adalta's shareholders